You are currently viewing Sanofi Introduces Verorab: A Game-Changer in Rabies Vaccination
Sanofi Introduces Verorab: A Game-Changer in Rabies VaccinationSanofi Introduces Verorab: A Game-Changer in Rabies Vaccination

Sanofi Introduces Verorab: A Game-Changer in Rabies Vaccination

The availability of rabies vaccines has been a pressing concern, but a ray of hope shines with the arrival of Sanofi’s Verorab®. This breakthrough vaccine replaces the HDC-inactivated rabies vaccine, heralding a new era in rabies prevention.

Restoring Immunization Against Rabies

A temporary shortage in rabies vaccines had posed significant challenges to rabies prevention efforts in Germany. However, with the introduction of Verorab®, this gap has been effectively bridged.

Innovative Manufacturing Process

Verorab®, unlike its predecessor HDC-inactivated rabies vaccine, is produced using Vero cells, a cell line derived from the kidneys of green monkeys. This transition in manufacturing ensures consistent and rapid supply across all regions, guaranteeing uninterrupted immunization against rabies.

Global Impact and Urgency

Rabies, a viral disease present in over 150 countries, claims approximately 59,000 lives annually. Despite its fatal nature, rabies is preventable through vaccination, making Verorab® a critical tool in combating this deadly virus.

Versatile Application and Safety Profile

Verorab® is approved in Germany for both pre-exposure and post-exposure prophylaxis against rabies across all age groups. Its efficacy and safety profile closely resemble those of the previous HDC-inactivated rabies vaccine, ensuring continuity in rabies prevention strategies.

Dosage and Administration

For pre-exposure prophylaxis, a regimen comprising three doses of 0.5 ml Verorab® administered intramuscularly on days 0, 7, and 28 (or 21) is recommended. The vaccine’s manufacture in France enhances supply chain independence and stability, bolstering its accessibility.

Proven Efficacy and Long-term Protection

Clinical trials have demonstrated Verorab®’s robust immune response in both pre-exposure and post-exposure prophylaxis settings. With a 96.6% sustained immune response over ten years post-booster vaccination, Verorab® offers enduring protection against rabies.

A Promising Future in Rabies Prevention

As the second rabies vaccine for pre- and post-exposure prophylaxis, Verorab® stands alongside Rabipur® by Bavarian Nordic A/S. Despite recent supply challenges, efforts are underway to ensure uninterrupted access to rabies vaccines, underscoring the critical role of Verorab® in global rabies prevention initiatives.

Original source: This information was Initially covered by pharmazeutische-zeitung and has been translated for our readers.

0 0 votes
Article Rating
Notify of
Inline Feedbacks
View all comments